Search clinical trials for: Bay 59-7939

Total 15007 results

Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Janssen Research & Development, LLC
Bayer

Completed

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Healthy

Belgium
Bayer

Completed

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Atrial Fibrillation

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer

Completed

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Janssen Research & Development, LLC
Bayer

Completed

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Healthy | Renal Insufficiency

United States
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers

Healthy

Belgium
Bayer
Janssen R&D, L.L.C.

Completed

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Japan
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer

Completed

Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXa-HIP2)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, France, Norway, United Kingdom
Bayer
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (XARIN)

Non-valvular Atrial Fibrillation (NVAF)

India
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Janssen Research & Development, LLC
Harvard Medical School (HMS and HSDM); Bayer; Duke Clinical Research Institute

Completed

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1)

Acute Coronary Syndrome

United States, France, Poland, Ukraine, Belgium, Spain, Argentina, Bulgaria, Russian Federation, Turkey, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Australia, Hungary, Sweden, Czechia, Denmark
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Bayer

Completed

Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXaHIP-OD)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, Norway, United Kingdom, France
Apitope International NV
Quintiles, Inc.; European Commission

Completed

ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

Graves Disease

United Kingdom
Benjamin Viglianti

Recruiting

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)

Hypertension | Cholesterol | Radiotracer

United States
Janssen Research & Development, LLC

Terminated

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection (PREVENT-HD)

Coronavirus Disease 2019 (COVID-19)

United States
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

Thrombosis | Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Pulmonary Embolism

Belgium, France, China, Switzerland, New Zealand, South Africa, Hungary, United States, Canada, Australia, Netherlands, Spain, Russian Federation, Austria, Mexico, Taiwan, Brazil, Czechia, Denmark, Germany, Israel, Italy, Korea, Republic... and more
Janssen Research & Development, LLC
Bayer

Completed

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

Heart Failure | Rheumatic Diseases | Respiratory Insufficiency | Infectious Diseases | Stroke Acute

United States, Poland, Ukraine, United Kingdom, Germany, Spain, Argentina, Belarus, Colombia, Israel, Mexico, Portugal, Bulgaria, Romania, Serbia, South Africa, Turkey, Canada, Australia, Netherlands, Denmark, Greece, Peru, Brazil, Russian... and more
Lille Catholic University
SSR pédiatrique Marc Sautelet

Recruiting

Evaluation of Cerebrospinal Fluid Flow in Adolescent Idiopathic Scoliosis (MEDULLOSCOL)

Adolescent Idiopathic Scoliosis

France
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

United States, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Australia, Canada, Netherlands, Denmark and more
Bayer

Completed

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

Atrial Fibrillation

Japan
AnaptysBio, Inc.

Recruiting

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)

Rheumatoid Arthritis

United States, Argentina, Estonia, Georgia, Hungary, Mexico, Moldova, Republic of, Peru, Poland, Slovakia, Belgium, Canada, Germany, Italy, Spain
National Institute of Allergy and Infectious Diseases...

Completed

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Influenza

United States
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Assiut University

Completed

Signaling Pathways Targeting Colorectal Cancer in Egypt

Colorectal Cancer

Egypt
National Institute of Allergy and Infectious Diseases...

Terminated

B-19 Parvovirus Vaccine Study

Parvovirus B19 Infection

United States
Innovative Medical

Completed

Oasys vs. Extreme H20 Xtra 59

Dry Eye

United States
Bayer
Janssen Research & Development, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Cytomegalovirus Infections

United States
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Public Health Clinical Center

Active, not recruiting

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Renal Cell Carcinoma

China
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital

Active, not recruiting

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (CAR)

Soft Tissue Sarcoma | Gastric Cancer | Pancreatic Cancer | Solid Tumor | Bladder Cancer

China
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (RECORD 2)

Venous Thromboembolism | Prevention

Denmark, Italy, China, Indonesia, Colombia, Portugal, United States, Australia, Korea, Republic of, Taiwan, Canada, Estonia, New Zealand, Brazil, Mexico, South Africa, Peru, United Kingdom, Latvia, India, Lithuania, Sweden, Norway
Jina Pharmaceuticals Inc.
Novum Pharmaceutical Research Services; Lambda Therapeutic Research Ltd.; Intas...

Recruiting

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Bipolar I Disorder

United States
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Withdrawn

Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
Hospices Civils de Lyon

Completed

S. Aureus, Skin and Soft Tissue Infections (SSTIs)

Skin and Soft Tissue Infections (SSTIs)

France
Hospices Civils de Lyon

Completed

Staphylococcus Aureus Nasal Carriage (SANAC)

Nasal Carriage of Staphylococcus Aureus

France
Hospices Civils de Lyon

Completed

Brain Maturation in Children With Localization Related Epilepsy (DYNAMAT)

Benign Childhood Epilepsy With Centro-temporal Spikes (BCECTS) | Focal Cryptogenic Epilepsy of Childhood | Cryptogenic Epilepsy of Childhood

France
Faculty Hospital Kralovske Vinohrady

Completed

The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry (LAPCOR)

Platelet Aggregation Onhibitors

Czechia
Bayer
Janssen Research & Development, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

United Kingdom

Search clinical trials for: Bay 59-7939

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations